EP
CYTK icon

Eversept Partners’s Cytokinetics CYTK Stock Holding History

Eversept Partners’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-126,877
Closed -$6.87M – 69
2024
Q2 		$6.87M Buy
+126,877
New +$7.66M 0.47% 38
2020
Q3 		– Sell
-141,700
Closed -$3.34M – 56
2020
Q2 		$3.34M Sell
141,700
-40,000
-22% -$750K 0.46% 35
2020
Q1 		$2.14M Hold
181,700
– – 0.53% 29
2019
Q4 		$1.93M Hold
181,700
– – 0.34% 51
2019
Q3 		$2.07M Buy
+181,700
New +$2.28M 0.64% 33

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Eversept Partners's CYTK Position: Q3 2024 in Review

Eversept Partners sold out of Cytokinetics (CYTK) in Q3 2024, closing a stake of 126,877 shares — an estimated $6.87M sold.

Eversept Partners first reported a position in CYTK in Q3 2019 and held it in 5 quarters. The position peaked at $6.87M in Q2 2024. 347 funds tracked by Wall St. Rank hold CYTK as of Q3 2024.

  • Eversept Partners reported no remaining Cytokinetics position as of Q3 2024 after selling out during the quarter.
  • Eversept Partners sold 126,877 Cytokinetics shares in Q3 2024, an estimated $6.87M.
  • Eversept Partners first reported a position in Cytokinetics in Q3 2019 and held it in 5 quarters.
  • Eversept Partners's Cytokinetics position peaked at $6.87M in Q2 2024.
  • 347 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2024.

Based on Eversept Partners's 13F filing for Q3 2024, filed 14 Nov 2024.